Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Muneerah M Aleissa"'
Autor:
Yazed S Alsowaida, Ahmad Alamer, Abrar K Thabit, Abdulaziz S Almulhim, Muneerah M Aleissa, Alireza Kalbasi, Khaled Eljaaly, Thamer A Almangour, Brian L Erstad
Publikováno v:
American Journal of Health-System Pharmacy. 80:503-517
Purpose Echinocandins are favored drugs for the treatment of fungal infections. There is growing evidence that obese patients treated with echinocandins have lower exposures due to pharmacokinetic (PK) alterations. We conducted a scoping review to ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::369e707bc88a9ee849c6dac1917a91b9
https://doi.org/10.1093/ajhp/zxad021
https://doi.org/10.1093/ajhp/zxad021
Autor:
Jessica S. Little, Muneerah M. Aleissa, Katherine Beluch, Isabel H. Gonzalez-Bocco, Francisco M. Marty, Jennifer Manne-Goehler, Sophia Koo, Sarah P. Hammond, Caron A. Jacobson
Publikováno v:
Blood Advances. 6:4821-4830
CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, although its use may be complicated by toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ce513beb52d67695bc4076bee810b6
https://doi.org/10.1182/bloodadvances.2022007474
https://doi.org/10.1182/bloodadvances.2022007474
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cellular therapies such as CAR-T therapy have excellent clinical efficacy for treatment of relapsed and refractory hematologic malignancies. Late neutropenia, occurring more than 30 days after CAR-T cell infusion, is a frequent complicatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b3cb37ccbdaa339f54f98f0835a402d
https://doi.org/10.1093/ofid/ofac492.1719
https://doi.org/10.1093/ofid/ofac492.1719
Autor:
Afoke Kokogho, Muneerah M Aleissa, Jun Bai Park Chang, Stephen R Walsh, Trevor A Crowell, Lindsey R Baden, Amy C Sherman
Publikováno v:
Open Forum Infectious Diseases. 9
Background SARS-CoV-2 vaccination reduces the risk and severity of coronavirus disease 2019 (COVID-19), but immunogenicity may be reduced in patients undergoing hematopoietic stem cell transplantation (HSCT). The variables that impact the humoral res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c7bdd0d9ca495458dd01eb8e86dc409
https://doi.org/10.1093/ofid/ofac492.914
https://doi.org/10.1093/ofid/ofac492.914
Autor:
Isabel H Gonzalez-Bocco, Matthew Cheng, Muneerah M Aleissa, Esther I Arbona, Kaiwen Chen, Eric Zhou, Katherine Beluch, Alyssa Cho, Sandra Burchett, Sarah P Hammond, Nicolas C Issa, Amy C Sherman, Francisco M Marty
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cytomegalovirus (CMV) disease is associated with increased morbidity and mortality following solid organ and hematopoietic cell transplantation. Currently, standard of care CMV treatments often have significant myelosuppressive or renal to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::619ec7075269089ace958d47493a9dc6
https://doi.org/10.1093/ofid/ofac492.024
https://doi.org/10.1093/ofid/ofac492.024
Autor:
Jessica S. Little, Roman M. Shapiro, Muneerah M. Aleissa, Austin Kim, Jun Bai Park Chang, David W. Kubiak, Guohai Zhou, Joseph H. Antin, John Koreth, Sarah Nikiforow, Corey S. Cutler, Rizwan Romee, Nicolas C. Issa, Vincent T. Ho, Mahasweta Gooptu, Robert J. Soiffer, Lindsey R. Baden
Publikováno v:
Transplantation and cellular therapy. 28(8)
The use of haploidentical donor hematopoietic cell transplantation (haploHCT) has expanded, but recent reports raise concern for increased rates of infectious complications. The incidence and risk factors for invasive fungal disease (IFD) after haplo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab5aec86cf22244b1db5efcdde3e2624
https://pubmed.ncbi.nlm.nih.gov/35526780
https://pubmed.ncbi.nlm.nih.gov/35526780
Autor:
Isabel H Gonzalez-Bocco, Muneerah M Aleissa, Eric Zhou, Jennifer Manne-Goehler, Sophia Koo, Matthew P Cheng, Francisco M Marty
Publikováno v:
Open Forum Infectious Diseases
Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin’s CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::444a8240cbef6d96bea63227a2c0ef2b
https://doi.org/10.1093/ofid/ofab582
https://doi.org/10.1093/ofid/ofab582
Autor:
Luisa M Paredes Acosta, Aaron Richterman, Francisco M. Marty, Muneerah M. Aleissa, Cameron T Nutt, Emily Silverman
Publikováno v:
Antimicrobial Agents and Chemotherapy
Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b886a09d5cc64a8a2fea9f706c42147
Autor:
Isabel H Gonzalez-Bocco, Muneerah M Aleissa, Matthew Cheng, Jennifer Manne-Goehler, Francisco M Marty
Publikováno v:
Open Forum Infectious Diseases
Background Non-tuberculous mycobacteria (NTM) are causes of pulmonary and extrapulmonary disease that frequently affect immunocompromised hosts (ICH). Current treatment guidelines recommend a macrolide-based, multi-drug regimen that includes rifampin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b51f770a449754109819a6b6db554ff5
http://europepmc.org/articles/PMC8643767
http://europepmc.org/articles/PMC8643767
Autor:
Anne M. McDonnell, Houry Leblebjian, Bashayer S. Alshehri, Marlise R. Luskin, Isabel H. Gonzalez-Bocco, Muneerah M. Aleissa, Francisco M. Marty
Publikováno v:
Leukemia Research. 108:106610
Gilteritinib is primarily metabolized via cytochrome P450 (CYP). Therefore, concomitant administration of strong CYP3A4 inducers or inhibitors is not recommended. We evaluated the incidence of gilteritinib-related adverse events (AEs) in 47 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83cdceebb018fb1aa4acfeb5f44e19b9
https://doi.org/10.1016/j.leukres.2021.106610
https://doi.org/10.1016/j.leukres.2021.106610